Athira Pharma Ownership | Who Owns Athira Pharma?
Athira Pharma Ownership Summary
Athira Pharma is owned by 7.73% insiders, and 92.27% retail investors. Simplify Propel Opportunities ETF is the top mutual fund, with 3.79% of its assets in Athira Pharma shares.
ATHA Ownership Benchmark
| Type | Name | % Inst | % Insiders | % Retail |
|---|---|---|---|---|
| Stock | Athira Pharma | - | 7.73% | 92.27% |
| Sector | Healthcare Stocks | 42.54% | 10.83% | 46.63% |
| Industry | Biotech Stocks | 45.22% | 10.75% | 44.04% |
Institutional Ownership Trends
| Date | Holdings | Change % | Shares | Change % | Ownership | Change % | Increased Position | Change % | Decreased Position | Change % |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2025 | 1 | -97.92% | 52 | -100.00% | - | - | - | -100.00% | 1 | -83.33% |
| Jun 30, 2025 | 50 | -7.41% | 17,507,224 | -0.33% | 44 | 2.21% | 17 | 88.89% | 6 | -66.67% |
| Mar 31, 2025 | 53 | -5.36% | 17,520,697 | -2.34% | 44 | 2.07% | 10 | -16.67% | 18 | -14.29% |
| Dec 31, 2024 | 54 | -8.47% | 17,895,389 | 10.96% | 46 | 2.65% | 12 | -52.00% | 21 | 50.00% |
| Sep 30, 2024 | 59 | -14.49% | 16,127,283 | -27.33% | 41 | 1.25% | 25 | 66.67% | 14 | -39.13% |
Top Mutual Funds Shareholders
| Holder | Shares | % Holding | Change |
|---|---|---|---|
| Simplify Propel Opportunities ETF | 1.49M | 3.79% | - |
| Vanguard US Total Market Shares ETF | 1.12M | 2.87% | - |
| Vanguard Total Stock Mkt Idx Inv | 1.05M | 2.66% | -22.94K |
| Wasatch Micro Cap | 646.90K | 1.68% | 646.90K |
| Wasatch Ultra Growth | 544.27K | 1.42% | 544.27K |
| Vanguard Institutional Extnd Mkt Idx Tr | 310.52K | 0.79% | -141.50K |
| DFA US Small Cap I | 88.44K | 0.23% | 3.34K |
| BlackRock Extended Equity Market K | 67.36K | 0.18% | -29.00 |
| Bridgeway Ultra-Small Company Market | 67.00K | 0.17% | -62.18K |
| iShares Micro-Cap ETF | 66.82K | 0.17% | - |
Recent Insider Transactions
| Date | Name | Role | Activity | Value |
|---|---|---|---|---|
| Jul 01, 2025 | CHURCH KEVIN | CHIEF SCIENTIFIC OFFICER | Sell | $2.50K |
| Jul 01, 2025 | Litton Mark James | President and CEO | Sell | $7.37K |
| Jul 01, 2025 | San Martin Javier | CHIEF MEDICAL OFFICER | Sell | $3.18K |
| Jul 01, 2025 | Worthington Mark | General Counsel and CCO | Sell | $2.50K |
| Jul 01, 2025 | Renninger Robert | SVP, Finance and Accounting | Sell | $850.27 |
Insider Transactions Trends
| Date | Buy | Sell |
|---|---|---|
| 2025 Q3 | - | 5 |
| 2025 Q2 | - | - |
| 2025 Q1 | - | 5 |
| 2024 Q4 | - | - |
| 2024 Q3 | - | 5 |
ATHA Ownership FAQ
Try Tickergate Pro Free
Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)
Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis
Discover trending investment themes
Find your next best investment
Research stocks using tools